Pfizer's aggressive mergers and acquisitions combined with in-house research and development have driven its growth portfolio to generate $3.1 billion in revenues in the first quarter of 2026, a 22% operational increase year-over-year. The risk from loss of exclusivity is reduced due to a delayed generic entry for Vyndamax until mid-2031, supporting management's forecast of high single-digit revenue growth over five years starting in 2029. While Pfizer's intermediate-term performance may fluctuate, its cost-saving initiatives, strong interest coverage, and sustainable dividends create a compelling investment case. The company’s discounted valuation and attractive dividend yields compared to peers facing similar patent challenges make it a great buy for investors willing to wait for eventual re-rating.
The Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) provides monthly income with a current 4.5% yield, focusing on stable, high-yield stocks from the S&P 500. Its dividends come from real cash flows of companies like Pfizer and Verizon, thoug...
Pfizer reported positive Phase 2 results for its 25-valent pneumococcal conjugate vaccine, showing much stronger immune responses against serotype 3 compared to PREVNAR 20. The vaccine could cover up to 90% of disease-causing serotypes in children un...
Johnson & Johnson (JNJ) is seen as having a superior return and risk profile compared to Pfizer (PFE), mainly due to its consistent dividend growth over 63 years, lower payout ratio, ongoing share buybacks, and stable inventory levels. While Pfizer o...
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...
